JP2023504733A - 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片 - Google Patents

抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片 Download PDF

Info

Publication number
JP2023504733A
JP2023504733A JP2022533579A JP2022533579A JP2023504733A JP 2023504733 A JP2023504733 A JP 2023504733A JP 2022533579 A JP2022533579 A JP 2022533579A JP 2022533579 A JP2022533579 A JP 2022533579A JP 2023504733 A JP2023504733 A JP 2023504733A
Authority
JP
Japan
Prior art keywords
seq
antibody
clec
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504733A5 (enExample
Inventor
エリゼ・シフォロー
ニコラ・ポワリエ
アリアヌ・ドゥセル
ヴィルジニー・テプニエ
カロリーヌ・マリー
ヴァネッサ・ゴーティエ
サブリナ・パンガム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantes Université
Original Assignee
Universite de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nantes filed Critical Universite de Nantes
Publication of JP2023504733A publication Critical patent/JP2023504733A/ja
Publication of JP2023504733A5 publication Critical patent/JP2023504733A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022533579A 2019-12-05 2020-12-04 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片 Pending JP2023504733A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306583.6 2019-12-05
EP19306583 2019-12-05
PCT/EP2020/084770 WO2021110990A1 (en) 2019-12-05 2020-12-04 Anti-clec-1a antibodies and antigen-binding fragment thereof

Publications (2)

Publication Number Publication Date
JP2023504733A true JP2023504733A (ja) 2023-02-06
JP2023504733A5 JP2023504733A5 (enExample) 2023-12-13

Family

ID=69232731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533579A Pending JP2023504733A (ja) 2019-12-05 2020-12-04 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片

Country Status (6)

Country Link
US (1) US20230331852A1 (enExample)
EP (1) EP4069372A1 (enExample)
JP (1) JP2023504733A (enExample)
CN (1) CN115151309A (enExample)
CA (1) CA3159155A1 (enExample)
WO (1) WO2021110990A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019295A (ko) * 2021-06-08 2024-02-14 오제 이뮈노테라프틱스 인간화 항-clec-1a 항체 및 이의 항원 결합 단편 및 이의 모방체
US20250026839A1 (en) * 2021-11-09 2025-01-23 Ose Immunotherapeutics Identification of CLEC-1 Ligand and Uses Thereof
EP4565607A1 (en) * 2022-08-01 2025-06-11 Ose Immunotherapeutics Heterodimeric fc-clec-1 fusion molecule and uses thereof
WO2025032213A1 (en) * 2023-08-10 2025-02-13 Ose Immunotherapeutics Identification of hla-dra as a ligand of clec-1 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073440A1 (en) * 2016-10-21 2018-04-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for promoting t cells response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US11248057B2 (en) * 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CA3035262A1 (en) * 2016-09-16 2018-03-22 Tina Christine Lavranos Antibody and checkpoint inhibitor combination therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073440A1 (en) * 2016-10-21 2018-04-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for promoting t cells response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOPEZ ROBLES MD. ET AL.: "Cell-surface C-type lectin-like receptor CLEC-1 dampens dendritic cell activation and downstream Th1", BLOOD ADVANCES, vol. 1, no. 9, JPN6024051723, 2017, pages 557 - 568, ISSN: 0005781112 *

Also Published As

Publication number Publication date
CN115151309A (zh) 2022-10-04
US20230331852A1 (en) 2023-10-19
WO2021110990A1 (en) 2021-06-10
CA3159155A1 (en) 2021-06-10
EP4069372A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
CN114716552B (zh) 人源化、小鼠或嵌合抗cd47单克隆抗体
CN102186884B (zh) 成纤维细胞生长因子受体-3（fgfr-3）抑制物
KR20210143192A (ko) 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
US20230331852A1 (en) Anti-clec-1a antibodies and antigen-binding fragment thereof
CN115192718A (zh) 抗cd47的单克隆抗体及其用途
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
TW202434644A (zh) 三特異性抗原結合分子及其應用
CN120958026A (zh) Fap/4-1bb/cd40结合分子及其医药用途
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
TW202434296A (zh) 一種ｆａｐ／ｃｄ４０結合分子的醫藥組成物及其醫藥用途
CN111375059B (zh) 一种抗gitr抗体药物组合物及其用途
US20260103526A1 (en) Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof
CN114829405A (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
WO2024145869A1 (en) Antibodies against axl and uses thereof
US20230242640A1 (en) ANTI-SIRPg Compounds
WO2024188331A1 (zh) 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途
CN115151572B (zh) 针对ror1的抗体及其用途
CN119816519A (zh) 抗ror1抗体、包含其的双特异性抗体及其用途
CN117545508A (zh) 用于癌的治疗和/或预防的药品
US20250296989A1 (en) ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
TWI843182B (zh) 一種抗b7-h4抗體及其製備方法和應用
HK40081642A (en) Anti-cd47 monoclonal antibody and use thereof
WO2025032213A1 (en) Identification of hla-dra as a ligand of clec-1 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127